---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-247168"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2022-09-19T23:59:59+00:00"
generated_at: "2026-06-23T08:51:11.517891+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics stockholders approve 2M share increase to 2017 Stock Incentive Plan

## Summary
- Stockholders approved amendment to 2017 Stock Incentive Plan, increasing authorized shares by 2,000,000 (total 4,608,374 for new awards).
- Vote: 11,537,809 for, 8,787,318 against, 3,114,531 abstentions, 4,552,916 broker non-votes.
- Directors Patrick Vink and Frank Thomas re-elected at annual meeting on September 15, 2022.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2022.

## SEC filing metadata
- accession: 0001193125-22-247168
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2022-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312522247168/0001193125-22-247168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312522247168/d371077d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-247168
- JSON: https://secwatch.observer/filing/0001193125-22-247168.json
- Plain text: https://secwatch.observer/filing/0001193125-22-247168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.